Amgen experimental lung cancer drug shows promise in study

Sept. 8, 2019

More than half of patients with an advanced form of lung cancer initially responded to an experimental Amgen drug that targets a genetic driver of the disease.

During the World Conference on Lung Cancer in Barcelona, Amgen presented results of a study that found that the highest dose of experimental AMG 510 shrank tumors in seven of 13 patients based on their first imaging scans post-treatment.

The findings are the first in patients for a KRAS inhibitor focused on a mutation known as G12C, giving Amgen the lead against rivals such as Johnson & Johnson.

The U.S. FDA granted the AMG 510 fast-track status for patients with metastatic non-small cell lung cancer with the G12C mutation.

Read the Bloomberg coverage